SRZN

Surrozen, Inc. (SRZN) - Q2 2025 10-Q Summary

Business Context and Reporting Period

Surrozen, Inc. is a biotechnology company focused on discovering and developing drug candidates to selectively modulate the Wnt pathway, with a current emphasis on ophthalmology. This report covers the quarterly period ended June 30, 2025. The company is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Note: Revenue consists entirely of research service revenue from a related party (TCGFB, Inc.).

Material Changes vs. Prior Period

• Profitability Shift: The company reported a net income of $39.75 million for Q2 2025, a significant turnaround from a net loss of $25.26 million in Q2 2024. This is primarily driven by non-cash accounting gains rather than operational profitability.
• Non-Cash Gains: Net income includes a $31.52 million gain on the change in fair value of tranche liability and a $16.22 million net other income (largely from changes in fair value of warrant liabilities). These non-cash items offset a $9.02 million operating loss.
• Capital Raise (2025 PIPE): In March 2025, the company executed a two-tranche private placement. The first tranche closed in March 2025, raising approximately $71.2 million in net proceeds. This significantly increased cash reserves from $34.6 million at year-end 2024 to $90.4 million.
• Warrant Liability Reduction: Total warrant liabilities decreased from $55.89 million (Dec 31, 2024) to $32.62 million (June 30, 2025) due to fair value adjustments and the cancellation of Series C and Series D warrants following the discontinuation of the SZN-043 program.
• Operating Expenses: Operating expenses increased by 13% year-over-year for the six-month period, driven by higher manufacturing and consulting costs for ophthalmology programs, partially offset by reduced clinical expenses due to the discontinuation of SZN-043.

Guidance, Outlook, and Risks

• Liquidity: Management believes existing cash of $90.4 million is sufficient to fund operations for at least the next 12 months. However, the company anticipates needing additional capital to advance clinical trials and regulatory submissions.
• Pipeline Updates:
  • SZN-8141 & SZN-8143: Lead candidates for retinal diseases (DME, wet AMD). The company expects to file an IND for SZN-8141 in 2026.
  • SZN-043 Discontinuation: Development was discontinued in Q1 2025 due to insufficient early clinical benefit signals in severe alcohol-associated hepatitis.
  • SZN-413: Collaboration with Boehringer Ingelheim continues; a $10 million milestone was triggered in September 2024.
• 2025 PIPE Tranche 2: A second tranche of approximately $98.6 million is contingent upon FDA clearance of the SZN-8141 IND application by October 31, 2026.
• Risks: Key risks include the high uncertainty of clinical trial outcomes, the need for future capital raises which may cause dilution, reliance on third-party manufacturers, and potential impacts of international trade tariffs on supply chains.

Investor Verification Checklist

• Non-Cash Income Quality: Verify the sustainability of net income by excluding the $47.6 million (Q2) and $104.6 million (YTD) in non-cash gains from tranche and warrant liability fair value changes.
• Cash Burn Rate: Confirm the actual cash burn from operations ($15.4 million used in operating activities YTD 2025) against the $90.4 million cash balance to validate the 12-month runway.
• PIPE Tranche 2 Conditions: Monitor the timeline for the SZN-8141 IND filing and FDA clearance, as the $98.6 million second tranche is contingent on this milestone by late 2026.
• Dilution Potential: Review the terms of outstanding warrants (Series E, Pre-funded warrants) and the tranche liability, which represent significant potential dilution if exercised or settled.
• Related Party Revenue: Assess the dependency on the TCGFB collaboration for the entirety of current revenue ($1.97 million YTD).